Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)

29. oktober 2026 oppdatert av: Yongchun Song, Tianjin Medical University Cancer Institute and Hospital

This single-center study evaluates a novel body position and breath-holding device for lung cancer patients receiving stereotactic body radiation therapy. We will enroll 50 patients with single peripheral non-small cell lung cancer, compare tumor movement and radiation dose distribution with and without the device, to test if the device is safe, feasible and can improve treatment accuracy.

Studieoversikt

Status

Påmelding etter invitasjon

Detaljert beskrivelse

For patients with peripheral non-small cell lung cancer receiving stereotactic body radiation therapy, respiratory motion often causes target volume deviation and compromises dose accuracy to tumors and nearby organs at risk. Current standard immobilization methods have limited ability to stabilize deep breathing patterns. This single-center translational study uses an integrated body position and breath-holding device, enrolling 50 eligible patients who will undergo 4DCT scans both with and without the device while keeping their clinical SBRT treatment plan unchanged. We will compare tumor motion amplitude, target coverage, conformity index and organ dose parameters between the two scanning states, to verify the device's feasibility, safety and value in improving treatment precision, providing clinical evidence for wider application in lung SBRT.

Studietype

Intervensjonell

Registrering (Antatt)

50

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Tianjin, Kina, 300000
        • Tianjin Medical University Cancer Institute and Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Voluntarily participate and sign written informed consent
  2. Age ≥18 years, gender unlimited
  3. Clinically diagnosed with single peripheral lung cancer, assessed as suitable for SBRT
  4. Males or females of childbearing age willing to take contraceptive measures during the trial
  5. Female of childbearing age must have a negative pregnancy test within 7 days before treatment, and all patients use adequate contraception during treatment and for 4 weeks after

Exclusion Criteria:

  1. Intolerant or unwilling to receive the integrated respiratory suppression and positioning immobilization device for radiotherapy localization.
  2. Currently participating or planning to participate in other clinical trials.
  3. Refuse or be unable to sign the informed consent form for this trial.
  4. Patients with central or ultra-central lung cancer.
  5. Patients planned to receive SBRT for multiple pulmonary lesions.
  6. Patients assessed by the investigators of this trial as unsuitable for SBRT treatment.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Single Arm - Novel Respiratory Immobilization

All enrolled patients receive 4DCT with and without the device

A novel immobilization device used for respiratory motion management during lung stereotactic body radiation therapy

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Mean respiratory motion amplitude of GTV and organs at risk (OARs) measured on 4DCT before and after abdominal pressure immobilization
Tidsramme: through study completion, an average of 1 year

Respiratory motion amplitude (maximum displacement) of gross tumor volume (GTV) and organs at risk (OARs) will be contoured and extracted from pre-abdominal-pressure 4DCT and post-abdominal-pressure 4DCT. The difference in motion amplitude between the two states will be compared to evaluate the feasibility and effectiveness of the novel abdominal pressure positioning membrane for lung SBRT.

through study completion, an average of 1 year

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Conformity index (CI) of SBRT planning target volume (PTV)
Tidsramme: At the time of SBRT plan design, prior to treatment delivery

CI of PTV calculated from SBRT dose distribution after abdominal pressure immobilization

At the time of SBRT plan design, prior to treatment delivery
Coverage of planning target volume (PTV)
Tidsramme: At the time of SBRT plan design, prior to treatment delivery

PTV coverage calculated from SBRT dose distribution after abdominal pressure immobilization

At the time of SBRT plan design, prior to treatment delivery
Maximum relative dose at 2 cm outside the PTV boundary (D2cm)
Tidsramme: At the time of SBRT plan design, prior to treatment delivery

Percentage of maximum dose at the region 2 cm outside PTV boundary on SBRT plan

At the time of SBRT plan design, prior to treatment delivery
Volume of normal ipsilateral lung receiving ≥20Gy,15Gy,10Gy and 5Gy (V20,V15, V10, V5)
Tidsramme: At the time of SBRT plan design, prior to treatment delivery

Dose-volume histogram parameters of normal treated lung from abdominal-pressure SBRT plan

At the time of SBRT plan design, prior to treatment delivery
Maximum dose (Dmax) to organs at risk including spinal cord, heart and esophagus
Tidsramme: At the time of SBRT plan design, prior to treatment delivery

Dmax of OARs derived from SBRT dose plan under abdominal pressure immobilization

At the time of SBRT plan design, prior to treatment delivery

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. september 2025

Primær fullføring (Antatt)

31. juli 2028

Studiet fullført (Antatt)

31. juli 2028

Datoer for studieregistrering

Først innsendt

19. oktober 2026

Først innsendt som oppfylte QC-kriteriene

29. oktober 2026

Først lagt ut (Faktiske)

4. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

This is an exploratory feasibility study, and no public sharing of individual patient data is planned.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere